AOD-9604 generates significant interest in the body composition and fat loss peptide community. It has a compelling scientific rationale — a fat-specific fragment of growth hormone that burns fat without the systemic effects of HGH — and a strong following among athletes and biohackers who have used it through gray-market channels.
For telehealth brand operators, the picture is more complicated. This guide covers what you need to know about AOD-9604’s regulatory status and what compliant alternatives are available for building a fat loss body composition program.
What AOD-9604 Is
AOD-9604 is a modified peptide derived from the last 16 amino acids of human growth hormone (residues 176 to 191), with an added tyrosine at the N-terminus to stabilize the compound. This C-terminal fragment of hGH was identified in research at the University of Melbourne and Metabolic Pharmaceuticals (an Australian company) as the region responsible for GH’s fat-burning effects — while the N-terminal portion is primarily responsible for growth, insulin-resistance, and other metabolic effects.
The theoretical elegance is real: a compound that delivers GH’s lipolytic mechanism without its risks.
Mechanisms of action:
- Beta-3 adrenergic receptor stimulation, which activates fat breakdown (lipolysis) in adipose tissue
- Inhibition of acetyl-CoA carboxylase, an enzyme involved in converting non-fat calories to fat
- No significant effect on IGF-1 (unlike full HGH, which raises IGF-1 significantly)
- No effect on blood glucose or insulin sensitivity at studied doses
The Clinical Trial History
Metabolic Pharmaceuticals conducted Phase 1, Phase 2, and Phase 3 clinical trials of AOD-9604 for obesity treatment in the early 2000s. The Phase 3 trial — a large, multi-center, randomized controlled trial involving over 500 patients — did not reach statistical significance on its primary endpoint of weight loss versus placebo.
This failed trial had two consequences:
- AOD-9604 was never approved as a pharmaceutical drug in any country
- Because it had been formally investigated as a new drug in human trials, it entered a regulatory category that complicates 503A compounding eligibility in the US
The FDA distinguishes between bulk drug substances that have never been studied as drugs (and may qualify for 503A compounding) versus substances that have been investigated under an IND (Investigational New Drug application) or submitted for NDA approval. AOD-9604’s history as an investigated new drug creates additional regulatory hurdles for compounding eligibility.
Why AOD-9604 Is Not Available for Compounding in the US
The FDA’s guidance on 503A bulk drug substances explicitly addresses compounds that have been investigated as new drugs. The agency’s position is that such compounds are subject to heightened scrutiny and may not be compounded if they are essentially copies of drugs that failed to receive approval.
A 2024 FDA response to a petition related to AOD-9604 compounding confirmed that the agency does not consider AOD-9604 eligible for inclusion on the 503A bulk drug substance list based on its new drug investigation history.
This means:
- US 503A compounding pharmacies cannot legally compound AOD-9604
- Any telehealth platform offering AOD-9604 as a US prescription is operating outside the legal compounding framework
- Products labeled as AOD-9604 available online are not pharmaceutical-grade and are being sold in a regulatory gray area
The Gray Market Problem
Like Melanotan II, AOD-9604 is widely sold through online vendors as a “research chemical.” These products carry the same risks as any non-pharmaceutical compound: unknown purity, inaccurate concentration labeling, contamination risk, and no physician oversight for dosing or contraindications.
Operators who direct patients toward gray-market AOD-9604 sources face significant legal and reputational risk. A compliant telehealth platform does not and cannot offer AOD-9604.
What to Use Instead: The Compliant Body Composition Stack
The good news for operators building body composition and fat loss programs is that highly effective compliant alternatives exist.
Tesamorelin: The Closest Clinical Substitute
Tesamorelin is an FDA-approved GHRH analog (approved as Egrifta SV for HIV-associated lipodystrophy) with a 503A compounding pathway. In the FDA’s approval trials, Tesamorelin produced an average 15.2 percent reduction in visceral adipose tissue — specifically abdominal fat — in treated patients.
Off-label, Tesamorelin is used by practitioners for general visceral fat reduction and body composition improvement. It works differently from AOD-9604 (stimulating the pituitary to release GH rather than directly activating beta-3 receptors), but the downstream effect on visceral fat is the most clinically documented fat-reduction outcome of any legally compoundable peptide.
CJC-1295 + Ipamorelin: The GH Secretagogue Stack
The CJC-1295 / Ipamorelin stack stimulates pulsatile GH release, which drives increased lipolysis, improved body composition, and enhanced recovery. While the primary framing is often growth hormone optimization and body composition, the fat loss outcomes for patients with GH deficiency or age-related GH decline are meaningful.
The Complete Compliant Body Composition Protocol
For visceral fat reduction: Tesamorelin For overall body composition (fat loss + lean mass): CJC-1295 + Ipamorelin For significant weight reduction: Semaglutide or tirzepatide (GLP-1 programs)
For more on building a body composition brand around these compounds, see How to Launch a Body Composition Peptide Telehealth Brand and How to Launch a Tirzepatide Weight Loss Brand.
Summary for Operators
| Compound | Status | Action |
|---|---|---|
| AOD-9604 | Not eligible for 503A compounding | Do not offer |
| Tesamorelin | 503A compoundable, FDA-approved indication | Primary alternative for visceral fat |
| CJC-1295 / Ipamorelin | 503A compoundable | Body comp stack |
| Semaglutide | Compounding restrictions tightened | GLP-1 — verify with pharmacy partner |
| Tirzepatide | 503A compoundable (shortage active) | Weight loss programs |
The body composition peptide market is large and the clinical tools to serve it are excellent. AOD-9604 is not one of them — at least not through a legal US telehealth channel. The compliant alternatives produce excellent outcomes and let you build a business you can stand behind.
Book a call with Karpa Health to build a compliant body composition peptide brand.
For more context on closely related topics, read GLP-1 compounding regulations guide.